Tevogen Bio Holdings Inc. (TVGN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on August 23, 2024, covering events occurring between August 20 and August 22, 2024. Tevogen Bio Holdings Inc., a Delaware corporation, reported the entry into a material definitive agreement for the issuance of Series C Preferred Stock, the resignation of a director, and the filing of a Certificate of Designation.
Key Financial Metrics and Capital Structure
The filing details a private placement transaction rather than standard operating financial results. Key metrics include:
- Capital Raised: $6.0 million aggregate purchase price.
- Instrument Issued: 600 shares of Series C Preferred Stock at $10,000 per share.
- Dividend Rate: 7.5% annual cumulative dividend, compounded annually.
- Dividend Commencement: The later of September 30, 2024, or the date full payment is received.
- Dividend Termination: Last business day of the quarter ending September 30, 2034.
- Liquidity Preference: Ranks junior to Series A and Series A-1 Preferred Stock but senior to Common Stock.
Material Changes and Corporate Actions
The following material changes were reported:
- Securities Purchase Agreement: On August 21, 2024, the Company entered into an agreement with an existing investor (The Patel Family, LLP, associated with Dr. Manmohan Patel) to purchase the Series C Preferred Stock.
- Conversion Terms: Shares are convertible into Common Stock beginning six months after issuance. The conversion price is the volume-weighted average price of Common Stock for the 30 trading days prior to exercise, subject to a floor price of $0.6172.
- Beneficial Ownership Limitation: Conversions are capped at 9.99% of outstanding Common Stock unless waived (up to a maximum of 19.99%). Excess shares are issued as pre-funded warrants with an exercise price of $0.0001.
- Board Resignation: Suren Ajjarapu resigned as a director effective August 21, 2024. The resignation was not due to any disagreement with the Company.
- Corporate Governance: The Company filed the Certificate of Designation for Series C Preferred Stock on August 22, 2024. The stock is non-voting but grants consent rights regarding amendments adverse to the stock.
Outlook, Risks, and Contingencies
The filing does not provide specific forward-looking guidance on revenue or operational milestones. However, the following terms present specific financial contingencies:
- Call Right: The Company has the right to call the Series C Preferred Stock at any time after the fifth anniversary of issuance for $10,000 per share plus accrued dividends.
- Liquidation Preference: In a liquidation event, holders receive the greater of the Original Issue Price plus accrued dividends or the as-converted value.
- Dividend Payment Method: Dividends are payable in shares of Series C Preferred Stock or, at the Company's election, in cash.
- Exemption: The transaction was conducted under Section 4(a)(2) of the Securities Act of 1933, exempt from registration.
Investor Verification Checklist
- Verify the total outstanding shares of Common Stock to assess the dilution impact of the 9.99% beneficial ownership limitation.
- Confirm the current status of Series A and Series A-1 Preferred Stock to understand the full capital structure hierarchy.
- Review the Company's cash position to determine if it can meet the 7.5% cumulative dividend obligation in cash or if it will issue additional preferred shares.
- Check the Company's recent stock price history to evaluate the likelihood of the $0.6172 conversion floor being triggered.
- Confirm the identity and relationship of "The Patel Family, LLP" to ensure full disclosure of related party transactions.